



University of
Zurich^{UZH}

ETH zürich

PhD Program in Cancer Biology

University of Zurich
c/o Institute of Molecular Cancer
Research
Winterthurerstrasse 190
CH-8057 Zurich
Phone: +41 44 635 34 52
<http://www.cb.uzh.ch>

Module B - Tumors and the Immune System 2024 - Hematologic Malignancies

Instructors

PD Dr. Beat Bornhauser
Dr. Susanne Kubetzko
Dr. Nicole Bodmer on behalf of
Prof. Jean-Pierre Bourquin

University Children's Hospital
Oncology
Steinwiesstrasse 75, CH-8032 Zurich
Jean-Pierre.Bourquin@kispi.uzh.ch

PD Dr. Stefan Balabanov
PD Dr. Alexandre Theocharides
Prof. Thorsten Zenz
Prof. Jana Ellegast
Prof Chiara Magnani

Hematology, University Hospital Zurich
Rämistrasse 100, CH-8091 Zürich
stefan.balabanov@usz.ch

Date Tuesday, April 9, 2024

Course Venue ETH, Gloriastrasse 35, ETZ E 81

General Outline

- 09:00-09:15 Intro PD. Dr. Stefan Balabanov
 - 09:15-10:00 lecture by PD. Dr. Stefan Balabanov, treatment of AML and CML
 - 10:00-10:45 lecture by PD Dr. Alexander Theocharides, clonal hematopoiesis
- Break
- 11:00-11:30 lecture by Prof Thorsten Zenz, experimental approaches for hematologic malignancies in adults
 - 11:30-12:00 lecture by Prof Jana Ellegast Experimental approaches for myeloid malignancies

Lunch

- 13:30-14:00 Dr. Nicole Bodmer, Experimental approaches for Childhood Leukemia
- 14:00-14:30 PD Dr. B Bornhauser, functional precision hematology, Drug Response Profiling

Break

- 14:45-15:30 T-cell engineering for hematological malignancies Prof Chiara Magnani
- 15:30-16:00 Molecular Diagnostics of Minimal Residual Disease according to EuroMRD Guidelines, Dr. Susanne Kubetzko
- Short closing by Dr. Susanne Kubetzko

Topics

The goal of this course is to provide an understanding of the development of modern oncology based the most relevant examples of human leukemia. We will illustrate how therapeutic concepts are developed in oncology and how important the close interconnection between cancer biology and hemato-oncology for the steady improvement of therapeutic options taking the complexity of each individual case into consideration.